Abstract:Breast cancer (BC) is the most common non-skin cancer and the second leading cause of cancer death in American women. The initiation and progression of BC can proceed through the accumulation of genetic and epigenetic changes that allow transformed cells to escape the normal cell cycle checkpoint control. Unlike nucleotide mutations, epigenetic changes such as DNA methylation, histone posttranslational modifications (PTMs), nucleosome remodeling and non-coding RNAs are generally reversible and therefore potentially responsive to pharmacological intervention. Epigenetic dysregulations are critical mechanisms for impaired antitumor immunity, evasion of immune surveillance, and resistance to immunotherapy. Compared to highly immunogenic tumor types, such as melanoma or lung cancer, breast cancer has been viewed as an immunologically quiescent tumor which displays a relatively low population of tumor-infiltrating lymphocytes (TIL), low tumor mutational burden (TMB) and modest response rates to immune checkpoint inhibitors (ICI). Emerging evidence suggests that agents targeting aberrant epigenetic modifiers may augment host antitumor immunity in BC via several interrelated mechanisms such as enhancing tumor antigen presentation, activation of cytotoxic T cells, inhibition of immunosuppressive cells, boosting response to ICI, and induction of immunogenic cell death (ICD). These discoveries have established a highly promising basis for using combinatorial approaches of epigenetic drugs with immunotherapy as an innovative paradigm to improve outcomes of BC patients. In this review, we summarize the current understanding of how epigenetic processes regulate immune cell function and antitumor immunogenicity in the context of the breast tumor microenvironment. Moreover, we discuss the therapeutic potential and latest clinical trials of the combination of immune checkpoint blockers with epigenetic agents in breast cancer.

Epigenetics and cutaneous neoplasms: from mechanism to therapy

Epigenetic Regulation in Cancer Therapy: from Mechanisms to Clinical Advances

Epigenetic Regulation and Cancer (Review).

Epigenetics Of Cutaneous T-Cell Lymphoma: Biomarkers And Therapeutic Potentials

Epigenetic regulation in the pathogenesis of non-melanoma skin cancer

Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression

Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises

A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors

Targeting epigenetics for cancer therapy

Epigenetics of colorectal cancer: biomarker and therapeutic potential

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Epigenetic Therapies and Potential Drugs for Treating Human Cancer

Epigenetics in Non-tumor Immune-Mediated Skin Diseases

Epigenetic Therapies and Potential Drugs for Treating Human Cancer.

Epigenetics Regulates Antitumor Immunity in Melanoma

Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases

Advances in Aberrant DNA Methylation in Cutaneous Malignancies

Current understanding of epigenetics role in melanoma treatment and resistance

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications

Epigenetics in Esophageal Cancer: from Mechanisms to Therapeutics